IE792471L - Galenical compositions - Google Patents

Galenical compositions

Info

Publication number
IE792471L
IE792471L IE792471A IE247179A IE792471L IE 792471 L IE792471 L IE 792471L IE 792471 A IE792471 A IE 792471A IE 247179 A IE247179 A IE 247179A IE 792471 L IE792471 L IE 792471L
Authority
IE
Ireland
Prior art keywords
preparations
active principle
core
gastric juice
ergot alkaloid
Prior art date
Application number
IE792471A
Other versions
IE49323B1 (en
Original Assignee
Sandoz Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz Ltd filed Critical Sandoz Ltd
Publication of IE792471L publication Critical patent/IE792471L/en
Publication of IE49323B1 publication Critical patent/IE49323B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The preparations for oral application comprise a coating resistant to gastric juice and a core comprise of an ergot alkaloid and of a sterile ester. The preparations are characterized by an improved and enhanced release of the active principle and a higher efficiency. The core may be comprised of a solid solution of the ergot alkaloid. The coating resistant to the gastric juice may be covered with an outer layer of the active principle. [GB2038181A]
IE2471/79A 1978-12-21 1979-12-19 Galenical compositions IE49323B1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CH1302178 1978-12-21
CH1301978 1978-12-21
CH56779 1979-01-19
CH56679 1979-01-19

Publications (2)

Publication Number Publication Date
IE792471L true IE792471L (en) 1980-06-21
IE49323B1 IE49323B1 (en) 1985-09-18

Family

ID=27427929

Family Applications (1)

Application Number Title Priority Date Filing Date
IE2471/79A IE49323B1 (en) 1978-12-21 1979-12-19 Galenical compositions

Country Status (23)

Country Link
AT (1) AT372279B (en)
AU (1) AU534051B2 (en)
CA (1) CA1139222A (en)
CH (1) CH642259A5 (en)
CY (1) CY1330A (en)
DE (1) DE2950154A1 (en)
DK (1) DK154607C (en)
FI (1) FI793888A7 (en)
FR (1) FR2444463A1 (en)
GB (1) GB2038181B (en)
HK (1) HK37986A (en)
HU (1) HU182577B (en)
IE (1) IE49323B1 (en)
IL (1) IL59003A (en)
IT (1) IT1164029B (en)
KE (1) KE3617D (en)
MY (1) MY8500129A (en)
NL (1) NL187229C (en)
NZ (1) NZ192457A (en)
PH (1) PH25178A (en)
PT (1) PT70614A (en)
SE (1) SE442265B (en)
WO (1) WO1980001242A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0064485B1 (en) * 1981-04-27 1985-07-24 Aktiebolaget Hässle New pharmaceutical preparation
US4366145A (en) * 1981-06-24 1982-12-28 Sandoz, Inc. Soft gelatin capsule with a liquid ergot alkaloid center fill solution and method of preparation
HU192050B (en) * 1983-04-22 1987-05-28 Sandoz Ag Process for production of medical preparative containing co-dergocrin and one piridin-dicarbonic acid diesthertype calcium-antagonist
DE3413955A1 (en) * 1983-04-22 1984-10-25 Sandoz-Patent-GmbH, 7850 Lörrach Pharmaceutical product containing co-dergocrine and a calcium antagonist
NL194389C (en) * 1984-06-14 2002-03-04 Novartis Ag Process for preparing a solid dispersion of a pharmaceutically active agent that has low water solubility in a solid matrix of a water-soluble polyalkylene glycol as a carrier.
GB8426922D0 (en) * 1984-10-24 1984-11-28 Sandoz Ltd Galenic formulation
AT388101B (en) * 1985-02-05 1989-05-10 Sandoz Ag Process for the production of a pharmaceutical composition for oral administration with controlled release of active ingredient
CN1003978B (en) * 1987-09-05 1989-04-26 广州陈李济药厂 Preparation process of spleen-tonifying and intestine-benefiting pills

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3432593A (en) * 1963-09-18 1969-03-11 Key Pharm Inc Delayed and sustained release type pharmaceutical preparation
DE2528257C2 (en) * 1974-07-04 1986-02-13 Sandoz-Patent-GmbH, 7850 Lörrach New galenic preparation
DE2546577B2 (en) * 1975-10-17 1981-04-02 Sandoz-Patent-GmbH, 7850 Lörrach Solid substances made from polyvinylpyrrolidone and ergot alkaloids

Also Published As

Publication number Publication date
CH642259A5 (en) 1984-04-13
CA1139222A (en) 1983-01-11
IT7951153A0 (en) 1979-12-20
DE2950154A1 (en) 1980-07-10
FR2444463A1 (en) 1980-07-18
MY8500129A (en) 1985-12-31
DK529879A (en) 1980-06-22
ATA803679A (en) 1983-02-15
IL59003A (en) 1982-12-31
IE49323B1 (en) 1985-09-18
NL7909105A (en) 1980-06-24
FI793888A7 (en) 1981-01-01
SE7910227L (en) 1980-06-22
AT372279B (en) 1983-09-26
HK37986A (en) 1986-05-30
SE442265B (en) 1985-12-16
DE2950154C2 (en) 1989-05-11
CY1330A (en) 1986-06-27
GB2038181A (en) 1980-07-23
DK154607C (en) 1989-06-05
NL187229C (en) 1991-07-16
KE3617D (en) 1986-04-18
PH25178A (en) 1991-03-27
HU182577B (en) 1984-02-28
AU534051B2 (en) 1984-01-05
DK154607B (en) 1988-12-05
AU5403179A (en) 1980-06-26
PT70614A (en) 1980-01-01
IT1164029B (en) 1987-04-08
WO1980001242A1 (en) 1980-06-26
FR2444463B1 (en) 1983-02-25
NZ192457A (en) 1983-06-17
GB2038181B (en) 1983-05-11

Similar Documents

Publication Publication Date Title
AU535198B2 (en) Preparation of clavulanic acid
DE2960106D1 (en) Aminoalkyl esters of pyridyloxy-phenoxy-alpha-propionic acids with herbicidal activity, their preparation, compositions containing them and their application
AU524193B2 (en) Clavulanic acid composition
JPS5539144A (en) Method of fabricating nb3sn composite superconductor
AU516719B2 (en) Preparation of cis-hexahydrodibenzopyranones
IL60127A (en) 3-phenoxybenzyl esters of 2-phenyl-alk-1-enyl-cyclopropane-carboxylic acid,their preparation and their use as insecticides and acaricides
AU519158B2 (en) Gasification of pellelized fuel
AU7171887A (en) Pellet for administration to ruminants
SE7910227L (en) GALENIAN COMPOSITIONS
AU1531976A (en) Method of manufacturing solar converter
AU525743B2 (en) Connection of tubing to non-tubular parts
AU559715B2 (en) Fatty acid formulation to protect gastric mucosa and liver against ethanol
IL56822A (en) Pentafluorobenzyl esters of substituted cyclopropanecarboxilic acids,their preparation and their use as insecticides and acaricides
AU5147679A (en) Preparation of 2-chlorosulfinylazetidinones
AU2557488A (en) Use of solar energy at high altitudes
IL57591A0 (en) The preparation of chlorostyryl-cyclopropane carboxylic acid derivatives
AU530948B2 (en) Pharmaceutical compositions with increased hypotensive effects
IE780532L (en) Lipogenesis - inhibiting compositions
IE780032L (en) Preparation of antidiarrheal agents
JPS5531096A (en) Novel compound bissindoline derivative active as drug and its manufacture
AU528112B2 (en) Preparation of straw through yeast fermentation
AU529069B2 (en) Preparation of tetramisole
DE2966065D1 (en) Derivatives of clavulanic acid, a process for their preparation and their compositions
AU526700B2 (en) Preparation of rosin esters
JPS54141796A (en) Clavulanic acid derivative*its composition and manufacture